Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moNELARABINE (nelarabine) by Gland Pharma is nucleic acid synthesis inhibitors [moa]. Approved for t-cell lymphoblastic lymphoma (t-lbl) in adult, older whose disease has not responded to, leukemia and 1 more indications. First approved in 2023.
Drug data last refreshed 1w ago
Nucleic Acid Synthesis Inhibitors
Worked on NELARABINE at Gland Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma
Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Observational Study of Nelarabine in Children and Young Adults
Drug Use Investigation for ARRANON G (Nelarabine) Injection 250mg
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo